drugset

drugset / Trial / NCT01092325

Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure

NCT01092325 ↗

Phase 1/2 Completed 28 enrolled Bristol-Myers Squibb Cardioxyl Pharmaceuticals, Inc · collab

RandomizedSingle-groupQuadruple-blindTreatment

Summary

A Phase 1-2a Study of CXL-1020-01 in Patients with Stable Heart Failure

Timeline

Start: 2009-06
Primary completion: 2010-05
Completion: 2010-05

Publications

Results A Phase I/IIa First in Man Safety and Tolerability Study of a Novel HNO Donor, CXL-1020, in Patients with Stable Congestive Heart Failure. Monday, April 4, 2011; 9:30 a.m. - 12:30 p.m., Ernest N. Morial Convention Center, Hall F; Poster Board #42
Sabbah HN, Tocchetti CG, Wang M, Daya S, Gupta RC, Tunin RS, Mazhari R, Takimoto E, Paolocci N, Cowart D, Colucci WS, Kass DA. Nitroxyl (HNO): A novel approach for the acute treatment of heart failure. Circ Heart Fail. 2013 Nov;6(6):1250-8. doi: 10.1161/CIRCHEARTFAILURE.113.000632. Epub 2013 Oct 9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CXL-1020	Other / unclassified	—	Intravenous

Indications